H.C. Wainwright Raises Protagonist Therapeutics, Inc. (PTGX) Target to $117, Reiterates Buy

We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy.

On January 30, H.C. Wainwright raised its price target on Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to $117 from $80 and reiterated a Buy rating. The firm cited the company’s track record in drug development and assigned probability-of-success assumptions across multiple programs, including PN-8047, its IL-4R antagonist, and obesity assets.

In early February, a company director sold 20,000 shares in a transaction valued at approximately $1.7 million, an event monitored by investors alongside ongoing pipeline developments. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) recently reported having two potential late-stage assets, Icotrokinra and Rusfertide, with NDAs submitted in 2025 for plaque psoriasis and polycythemia vera, respectively. The company also expects multiple Phase 2 and Phase 3 readouts across immunology, hematology, and obesity indications. Existing partnerships with Johnson & Johnson and Takeda include milestone and royalty structures that support non-dilutive funding.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) was founded on August 22, 2006, and is headquartered in Newark, California. The company develops peptide-based therapies targeting rare diseases, hematology, and immunology.

While we acknowledge the potential of PTGX as a long term investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 8 Up and Coming Streaming Companies and Services and 9 High Growth Canadian Stocks to Buy

Disclosure: None.